STOCK TITAN
  1. Home
  2. News
  3. INBS

Intelligent Bio Solutions Inc. - INBS STOCK NEWS

Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.

Intelligent Bio Solutions Inc. (INBS) is a progressive life sciences company committed to enhancing health care through innovative non-invasive diagnostic tests. The company's primary focus lies in developing real-time monitoring solutions that aid patients and health practitioners in managing chronic diseases efficiently. Through its cutting-edge Biosensor Platform, Intelligent Bio Solutions Inc. is pioneering diagnostic tests that are urgently required to improve patient outcomes and streamline medical diagnostics.

One of the company's significant advancements is in the realm of portable drug abuse testing. Utilizing fingerprint sweat analysis, INBS offers a non-invasive, hygienic, and rapid drug screening solution. This technology is engineered to detect the recent use of substances such as opioids, cocaine, methamphetamines, benzodiazepines, and marijuana, making it an invaluable tool in both clinical and legal settings.

Intelligent Bio Solutions Inc. has demonstrated substantial growth and success, as evidenced by an impressive year-over-year unaudited revenue increase of 80% for the fiscal third quarter and 193% for the nine months ending March 31, 2024. The company also reported its highest quarterly cartridge sales since acquiring Intelligent Fingerprinting in 2022, highlighting the growing demand and effectiveness of its products.

For more information, visit: http://www.ibs.inc/.

News

Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on December 7, 2023

Rhea-AI Summary
Intelligent Bio Solutions Inc. (Nasdaq: INBS) will present at the Emerging Growth Conference on December 7, 2023. The Company will showcase its proprietary Intelligent Fingerprinting Drug Screening System. Harry Simeonidis, President and CEO, will present at 2:20 p.m. Eastern Time. An archived webcast will be available on emerginggrowth.com and the Emerging Growth YouTube Channel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.91%
Tags
conferences acquisition
-
News

Australian Civil Construction Entity, State Road Constructions, Selects Intelligent Fingerprinting Drug Screening System as Workplace Drug Screening Solution

Rhea-AI Summary
Intelligent Bio Solutions Inc. (INBS) announced that State Road Constructions selected its Intelligent Fingerprinting Drug Screening System for workplace drug screening. The system offers non-invasive, rapid drug testing using fingertip sweat, aligning with State Road's dedication to operational efficiency. It detects major drugs of abuse within a 14-16 hour window, maintaining employee privacy and workplace safety. The system's portability makes it suitable for safety-critical industries like construction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
none
-
News

Intelligent Bio Solutions Inc. Reports Fiscal 2024 First Quarter Financial Results and Operational Highlights

Rhea-AI Summary
INBS (Nasdaq: INBS) reported a 191% year-over-year increase in combined revenue and government support income for the first fiscal quarter ended September 30, 2023, reaching $0.91 million. The company also achieved an 88% sequential increase due to strong organic growth and expansion plans. INBS expanded into the South American market, advanced plans for the U.S. market, and completed a critical development milestone for new assays for its Intelligent Fingerprinting Drug Screening System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
92.51%
Tags
earnings
News

Intelligent Bio Solutions’ Innovative Drug Screening Technology Now Offered in New Zealand

Rhea-AI Summary
Intelligent Bio Solutions Inc. expands into the New Zealand market with its Intelligent Fingerprinting Drug Screening System, aiming to meet the screening needs of businesses and support health and safety initiatives. The system offers a non-invasive alternative to traditional drug testing methods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
none
-
News

Intelligent Bio Solutions Adds Logistics Firm to Fingerprint Drug Screening Portfolio and Completes Major Milestone with Existing Client

Rhea-AI Summary
Intelligent Bio Solutions announces adoption of its Intelligent Fingerprinting Drug Screening System by VKVP Haulage and successful completion of 25,000 tests by Auctus Management Group
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.14%
Tags
none
-
News

Intelligent Bio Solutions Inc. Announces Closing of $4.378 Million Underwritten Public Offering Including Partial Exercise of Underwriters’ Overallotment Option

Rhea-AI Summary
Intelligent Bio Solutions Inc. closes underwritten public offering of units for $4.378 million, with proceeds to be used for general corporate purposes and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.14%
Tags
offering
News

Intelligent Bio Solutions Inc. Announces Pricing of $4,000,000 Underwritten Public Offering

Rhea-AI Summary
Intelligent Bio Solutions Inc. announces pricing of underwritten public offering of units for $4.0 million. Offering consists of 7,272,727 shares of common stock, warrants, and convertible preferred stock. Proceeds to be used for general corporate purposes and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-53.5%
Tags
offering
-
News

Intelligent Bio Solutions Obtains ISO Recertification for its Intelligent Fingerprinting Drug Screening Business

Rhea-AI Summary
Intelligent Bio Solutions Inc. (Nasdaq: INBS) has obtained recertification for ISO 13485:2016, a quality management system standard for the medical device industry. The recertification is valid for three years and supports the company's expansion plans into North America and Asia Pacific regions. The ISO 13485:2016 certification confirms the company's ability to meet the highest quality criteria globally. The company's Intelligent Fingerprinting Drug Screening System has gained positive feedback from over 350 clients worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Intelligent Bio Solutions Completes Critical Development Milestone in Plans to Add Ketamine and Tramadol to Fingerprint Drug Test

Rhea-AI Summary
Intelligent Bio Solutions announces successful completion of key milestone in adding ketamine and tramadol to its drug screening system
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
none
News

Intelligent Bio Solutions Inc. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Operational Highlights

Rhea-AI Summary
Intelligent Bio Solutions reports 355% YoY increase in combined revenue and government support income, receives FDA guidance on regulatory pathway for Intelligent Fingerprinting Drug Screening Cartridge, and secures 8 new customers in Australia. Net loss for FY 2023 was $10.6M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
earnings

FAQ

What is the current stock price of Intelligent Bio Solutions (INBS)?

The current stock price of Intelligent Bio Solutions (INBS) is $1.41 as of November 4, 2024.

What is the market cap of Intelligent Bio Solutions (INBS)?

The market cap of Intelligent Bio Solutions (INBS) is approximately 5.9M.

What does Intelligent Bio Solutions Inc. specialize in?

Intelligent Bio Solutions Inc. specializes in developing non-invasive, real-time monitoring and diagnostic tests for managing chronic diseases and portable drug abuse testing.

What is the Biosensor Platform?

The Biosensor Platform is a technology developed by INBS for creating real-time diagnostic tests to assist in managing chronic illnesses and other medical conditions.

How does INBS's drug abuse testing technology work?

INBS uses fingerprint sweat analysis to offer a non-invasive, hygienic, and quick method of screening for recent drug use, including opioids, cocaine, and more.

What recent financial achievements has Intelligent Bio Solutions Inc. reported?

The company reported an 80% increase in year-over-year unaudited revenue for the fiscal third quarter and a 193% increase for the nine months ending March 31, 2024.

When did INBS achieve its highest quarterly cartridge sales?

INBS reported its highest quarterly cartridge sales since 2022, following the acquisition of Intelligent Fingerprinting.

Who are the primary contacts for Intelligent Bio Solutions Inc.?

Company-related inquiries can be directed to info@ibs.inc. For media-related queries, contact Cheryl Billson at cheryl.billson@commacomms.com or Valter Pinto at INBS@kcsa.com.

Where can I find more information about the company?

For more information about Intelligent Bio Solutions Inc., visit their official website at http://www.ibs.inc/.

What chronic diseases does INBS focus on with its diagnostic tests?

INBS focuses on creating diagnostic tests that assist in the management of various chronic diseases, though specific conditions are not detailed.

What substances can INBS's drug screening test detect?

INBS's drug screening test can detect recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.

How does the fingerprint sweat analysis benefit users?

The fingerprint sweat analysis is non-invasive, hygienic, and fast, providing a convenient and reliable method for drug abuse testing.

Stock INBS logo
Intelligent Bio Solutions Inc.

Nasdaq:INBS

INBS Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

INBS Stock Data

5.95M
4.25M
3.02%
14.38%
8.69%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW YORK